Coronavirus has shifted the focus of the entire sector. In 2019, the consultancy firm EY found that the biggest pharma companies worldwide were concentrating on cancer, with 2,586 drugs in clinical development compared with only 605 anti-infection medications. That’s now changing.
“We can expect that, thanks to the coronavirus crisis, topics like infection and antibiotic resistance will come to the fore,” says Siegfried Bialojan, head of EY’s Life Science Center in Germany.
Covid-19’s other major impact has been on sourcing strategies – many firms are reassessing their dependence on suppliers in India or China – and in the digital realm. The pharma industry has been forced online, digitalizing everyday tasks and working on healthcare concepts that go “beyond pills.”